转化生长因子β和膜肌肉肉瘤:瘤分化和化疗反应的挑战
Bhavya Bhushan1,2, Rosa Iranpour1, Amirmohammad Eshtiaghi1
1Department of Human Anatomy and Cell Science, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0W2, Canada.
International journal of molecular sciences
|March 13, 2024
概括
膜性狂肌肉瘤 (ARMS) 涉及融合基因和转化生长因子β (TGF-β) 的过度表达,阻碍分化并增加化学抵抗. 针对TGF-β1信号传递可能会改善ARMS治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 膜性狂肌肉瘤 (ARMS) 是一种具有攻击性的癌症亚型,其特征是特定的染色体转位,导致PAX3-FOXO1或PAX7-FOXO1.1等瘤性融合基因.
- 患有ARMS的患者经常表现出转化生长因子β (TGF-β) 的过度表达,这种细胞因子通过SNAIL促进表皮细胞转化为介质细胞转化 (EMT),并抑制肌体分化,从而导致化疗耐药性.
研究的目的:
- 本综述侧重于TGF-β信号在ARMS发展和进展中的作用.
- 它旨在巩固目前关于ARMS的知识,TGF-β的影响以及现有和新兴的化疗策略.
主要方法:
- 综述现有关于肌肉瘤亚型的文献,重点关注ARMS.
- 对涉及TGF-β,SNAIL和ARMS中的肌原分化的分子机制的分析.
- 在ARMS治疗中使用的当前和试验性化疗剂的汇编.
主要成果:
- 在ARMS中TGF-β1过度表达驱动EMT并抑制肌原分化,导致治疗结果差.
- 目前的化疗方案包括VAC,卡博赞提尼布,博特佐米布,维诺雷尔宾,AZD 1775和西斯丁.
- 像全转网红酸 (ATRA) 和5-阿扎丁这样的药物正在被探索,因为它们有可能诱导瘤细胞分化.
结论:
- 了解TGF-β1信号通路对于开发ARMS的向疗法至关重要.
- 未来的研究应该专注于根据分子途径的洞察来定制药物管理,以提高ARMS治疗疗效.
相关概念视频
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


